

Clinical Outcomes of Direct-Acting Oral Anticoagulants in COVID-19 Patients with Cardiometabolic Comorbidities at a Tertiary Care Hospital

Sabeen Fatima^{1*}, Shizra Kaleemi², Noor ul Huda³, Fatima Hafeez⁴, Asma Akhtar⁵, Samreen Khan⁶

ABSTRACT

OBJECTIVE: To evaluate the thrombotic and hemorrhagic outcomes with DOACs in COVID-19 patients with Cardiometabolic diseases that can help in future to treat COVID patients and combat the pandemic.

METHODOLOGY: A descriptive study was conducted among COVID-19 patients in the COVID-19 Isolation Wards and the ICU of Nishtar Medical University, Multan, Pakistan, from January to June 2022. A total of 121 patients who met the inclusion criteria were enrolled in the study. All the patients were put on DOAC therapy, either Rivaroxaban, Apixaban, Edoxaban or Dabigatran. We followed them for up to 30 days after COVID-19 diagnosis to assess the development or absence of thrombotic or hemorrhagic events. Data were analyzed using SPSS 23.

RESULTS: Mean age of the participants was 60.0 ± 10.7 years. Over a period of 30-day follow-up with DOACs, 38.9% of patients developed hemorrhage and 28.9% developed thrombosis. The frequency of thrombosis was significantly higher in males compared to females (36.9% vs 19.6%; p-value 0.037), and higher in obese compared to non-obese (42.1% vs 22.9%, p-value 0.031). The frequency of thrombosis differed significantly among DOACs, with the highest rate in Dabigatran (50%) and the lowest in Rivaroxaban (17.4%).

CONCLUSION: Our study found that haemorrhage occurred in 38.9% of patients on DOACs, and thrombosis was lowest (17.4%) in patients on Rivaroxaban compared to other DOACs. Therefore, Rivaroxaban is associated with a lower frequency of thrombosis.

KEYWORDS: COVID-19, Cardiometabolic, Anticoagulants, Obesity, Thromboembolism

INTRODUCTION

SARS-CoV-2, a recently discovered novel coronavirus that causes a lethal and contagious disease, was named Coronavirus (COVID-19) and declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Cardiometabolic disease is most prevalent in COVID-19 patients and linked to worse COVID-19 outcomes, such as death, mechanical ventilation, and intensive care, as well as higher susceptibility to the coronavirus². Cardiometabolic disease refers to a group of metabolic abnormalities (such as poor lifestyles, poor diets, obesity,

pathological changes like insulin resistance, hyperglycemia, dyslipidemia, abdominal obesity, and hypertension) that increase the risk of cardiovascular diseases and type 2 diabetes². Thrombotic events are common and often fatal in patients with COVID-19, particularly among those with pre-existing cardiometabolic diseases and cardiovascular disease³. According to a previous study, the prevalence of thrombotic complications stands at 43%, while haemorrhagic complications occur in 8% of cases in COVID-19 patients⁴. Haemorrhage is bleeding from a damaged or ruptured blood vessel, while thrombosis is the formation of blood clots⁴. Thrombotic events are associated with considerable mortality and morbidity because of high ferritin levels, complement dysfunctions, and macrophage activation⁵. COVID-19 induces a hypercoagulable state driven by endothelial dysfunction and a systemic inflammatory response. This cooperation significantly increases the risk of arterial and venous thrombosis⁶, with a particularly high prevalence of thromboembolic complications among critically ill patients⁷.

Anticoagulants have a significant role in the treatment of cardiovascular and thromboembolic diseases⁸. Warfarin (vitamin K antagonists) and direct-acting oral anticoagulants (DOACs) are commonly used anticoagulants recommended for thrombosis, and their role in thromboprophylaxis of cardiometabolic diseases is also well established⁸. DOACs in COVID-

¹ Assistant Professor of Hematology, Incharge Pathology lab and Blood Bank, Tertiary care Hospital, Nishtar II, Multan, Pakistan.

² Assistant Professor, Department of Pathology, Al-Aleem Medical College/Gulab Devi Teaching Hospital, Lahore, Pakistan.

³ Consultant Hematologist Central Hospital, Gujranwala, Pakistan

⁴ Senior Demonstrator, Pathology, Bakhtawar Amin Medical College, Multan, Pakistan

⁵ Assistant Professor, Haematology, Shalamar Medical and Dental College, Shalamar Institute of Health Sciences, Lahore, Pakistan.

⁶ Consultant Hematologist, Islamabad Diagnostic Centre (IDC), Islamabad, Pakistan.

*Correspondence: sabeenfatima@hotmail.com

doi: 10.22442/jlumhs.2026.01426

Received: 02-12-2025

Revised: 23-02-2026

Accepted: 26-02-2026

Online First: 06-04-2026



19 patients significantly increase hemorrhage risk due to severe drug-drug interactions and virus-induced physiological changes⁴. However, their efficacy in preventing stroke and systemic embolism, combined with lower rates of intracranial haemorrhage, gives them a superior safety profile compared with traditional Vitamin K antagonists⁸. Further, DOACs do not require regular laboratory monitoring as compared to warfarin and are not affected by food or alcohol⁸. DOACs consist of a factor IIa inhibitor, such as Dabigatran, and three factor Xa inhibitors, such as Rivaroxaban, Apixaban, and edoxaban⁸. Like Dabigatran, the Factor Xa inhibitors rivaroxaban, Apixaban, and Edoxaban have been linked to successful treatment and prevention of recurrent venous thromboembolism (VTE)^{9,10}, as well as a decreased incidence of significant haemorrhage¹¹. DOACs are generally preferred over traditional anticoagulants, but head-to-head evidence is critically lacking of identify which specific treatment (Apixaban, Rivaroxaban, edoxaban, or Dabigatran) optimizes the balance for the high-risk phenotype. There is a lack of local data on DOAC-associated outcomes in COVID-19 patients with cardiometabolic diseases.

This study aims to describe thrombotic and hemorrhagic outcomes with different DOACs in hospitalized COVID-19 patients with cardiometabolic diseases, and to identify the best DOAC treatment among different types to help in the future treatment of COVID-19 patients, combat the viral pandemic, and generate local observational data on DOAC-associated outcomes in COVID-19 patients with cardiometabolic diseases. Therefore, we conducted a prospective observational study of hospitalized COVID-19 patients receiving DOAC therapy to systematically document clinical outcomes over 30 days.

METHODOLOGY

Study design

We conducted a descriptive study of 121 COVID-19 patients from January to June 2022 in the COVID Isolation Wards and the ICU of Nishtar Medical University, Multan, Pakistan, using non-probability consecutive sampling. Informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Sample size

The sample size of 121 was calculated using the WHO software using the formula for a single proportion⁹. Frequency of thrombotic events (both arterial and venous thrombosis) = 8.5%, Confidence level = 95%, Margin of error = 05%.

Inclusion and exclusion criteria

Patients of both genders, males and females, between the age group of 35-80 years, suffering from one or more cardiometabolic diseases (diabetes, hypertension or obesity), and COVID-19 confirmed patients tested with PCR were included in the study, specifically those not on anticoagulation therapy. We also included patients with leukaemia/lymphoma in the

second and third trimesters of pregnancy, as DOACs are safe to use. At the same time, pregnant ladies in the first trimester were excluded, as DOACs are not approved by the FDA to be given to pregnant ladies in the first trimester. Patients who failed to follow up after 30 days, those who died within 7 days of admission in COVID isolation or ICU ward, individuals with inherited bleeding or thrombophilia disorders, non-compliant patients refusing DOACs, and those with a prior history of DVT or thrombosis were also excluded from this study.

Data collection procedure

After obtaining ethical review committee approval (No. 4120; Dated 09-03-2022), the PCR-positive COVID-19 patients admitted to the COVID isolation ward and ICU of Nishtar Hospital with cardiometabolic diseases (as per the patient's previous medical records) were included in the study. We conducted detailed history and general physical examinations using non-probability sampling and documented them on a specially designed pro forma. Clinical outcomes were assessed according to standardized symptomatic presentations. Thrombotic events were identified by signs of deep vein thrombosis (DVT), such as localized pain, swelling, warmth, and redness in the limbs, or by pulmonary embolism (PE), characterized by chest pain and dyspnea. Arterial thrombosis was defined by neurological deficits (sudden confusion, speech difficulties, hemiparesis, or severe headache) or cardiac distress (intense chest pain, dizziness, and respiratory distress). A brain haemorrhage was identified through sudden severe headache, vision changes, or loss of consciousness. Internal hemorrhage (abdominal/organ-specific) was noted via abdominal swelling, pain, fatigue, and hematemesis or melena. Chest hemorrhage (hemothorax) was marked by coughing up blood and chest pain, and musculoskeletal hemorrhage was recorded in cases of severe bruising and joint-specific swelling and pain. Participants received DOAC therapy for COVID-19 management according to standard clinical protocols, with the treating physician determining the specific agent and dose. Therapeutic regimens included Rivaroxaban (15 mg BID), Apixaban (initiated at 10 mg BID for the first 7 days, then reduced of 5 mg BID), Edoxaban (60 mg QD), or Dabigatran (150 mg BID). All medications were administered orally. Patients were monitored for 30 days post-COVID-19 diagnosis to assess the occurrence or absence of thrombotic and hemorrhagic complications. Diagnostic verification of suspected events was conducted using specialized imaging modalities: color Doppler ultrasound for DVT, computed tomography pulmonary angiography (CTPA) for pulmonary embolism, and angiography for acute myocardial infarction, cerebral infarction, and cerebral venous thrombosis. All diagnostic procedures were performed at the Radiology Department of Nishtar Hospital, Multan, Pakistan, where these advanced facilities are fully operational. The Nishtar Hospital Outpatient Department (OPD) provided

essential medications free of cost as part of the public healthcare initiative, and the primary investigators personally funded all remaining investigative costs.

Data analysis

Data were analyzed on SPSS version 23.0. Descriptive statistics were employed to summarize the data. Continuous variables (such as age and BMI) were expressed as mean $\pm$ standard deviation (SD). Categorical variables (such as gender, age groups, residential status, diabetes mellitus, hypertension, obesity, and clinical outcomes) were reported as frequencies and percentages. To address potential confounding, stratification was performed for effect modifiers, including gender, age, residential status, and comorbidities (diabetes, hypertension, and obesity). We then applied the chi-square test to these stratified groups to assess the association between these variables and the thrombotic/hemorrhagic outcomes of DOAC therapy. A p-value of ≤ 0.05 was considered statistically significant.

RESULTS

The mean age of the participants was 60.0 ± 10.7 years. Males accounted for 53.7% (n=65) and females for 46.3% (n=56). The mean body mass index (kg/m^2) of the patients was 26.6 ± 2.3 . 47.9% (n=58) of patients came from rural areas and 52.1% (n=63) from urban areas. There were 31.4% (n=38) obese, 55.4% (n=67) diabetics and 66.9% (n=81) hypertensives in the study group (Table I).

Table I: Characteristics of COVID-19 patients with cardiometabolic conditions (N=121)

Factors	Categories	Statistical values	Results
Age (Years)	-----	mean $\pm$ SD	60.0 $\pm$ 10.7
Body mass index (kg/meter^2)	-----	mean $\pm$ SD	26.6 $\pm$ 2.3
Gender	Male	n (%)	65 (53.7)
	Female	n (%)	56 (46.3)
Obesity	Yes	n (%)	38 (31.4)
	No	n (%)	83 (68.6)
Area of residence	Rural	n (%)	58 (47.9)
	Urban	n (%)	63 (52.1)
Diabetes Mellitus	Yes	n (%)	67 (55.4)
	No	n (%)	54 (44.6)
Hypertension	Yes	n (%)	81 (66.9)
	No	n (%)	40 (33.1)

*SD=standard deviation, n=Number of patients, %=percentage

Most commonly prescribed direct-acting oral anticoagulants (DOACs) were Rivaroxaban in 38% (n=46), followed by Apixaban in 33.9% (n=41), Edoxaban in 19.8% (n=24) and Dabigatran in 8.3% (n=10) (Figure 1A). Over a 30-day follow-up period, 38.9% (n=47) developed haemorrhage (bleeding risk),

and 28.9% (n=35) developed thrombosis (blood clotting risk) (Figure 1B).




Figure 1: Frequency of directly acting oral anticoagulants (DOACs) to patients with COVID-19 (A) and frequency of outcomes in COVID-19 patients on directly acting oral anticoagulant therapy (B)

The frequency of thrombosis was significantly higher in males compared to females (36.9% vs 19.6%; p-value 0.037), higher in obese compared to non-obese (42.1% vs 22.9%; p-value 0.031) and higher in patients from rural areas compared to urban areas (37.9% vs 20.6%; p-value 0.036). However, age, diabetes mellitus and hypertension did not significantly affect the occurrence of thrombosis (Table II). The frequency of thrombosis differed significantly among DOACs, with Dabigatran (50%), Edoxaban (45.8%), and Rivaroxaban (17.4%) in descending order (Table III). Age, gender, area of residence, obesity, diabetes mellitus and hypertension did not significantly affect the frequency of Hemorrhage in COVID-19 patients on DOACs (Table IV).

Table II: Effect of age, gender, area of residence, obesity, diabetes mellitus and hypertension on frequency of Thrombosis in COVID-19 patients on DOACs (N=121)

Factors		Thrombosis		p-value*
		Yes	No	
Age Groups	Up to 60 years	20 (34.5)	38 (65.5)	0.196
	> 60-years	15 (23.8)	48 (76.2)	
Gender	Male	24 (36.9)	41 (63.1)	0.037
	Female	11 (19.6)	45 (80.4)	
Obesity	Yes	16 (42.1)	22 (57.9)	0.031
	No	19 (22.9)	64 (77.1)	
Area of residence	Rural	22 (37.9)	36 (62.1)	0.036
	Urban	13 (20.6)	50 (79.4)	
Diabetes Mellitus	Yes	21 (31.3)	46 (68.7)	0.514
	No	14 (25.9)	40 (74.1)	
Hypertension	Yes	24 (29.6)	57 (70.4)	0.808
	No	11 (27.5)	29 (72.5)	

*Chi-square test

Table III: Frequency of thrombosis among different DOACs in COVID-19 patients (N=121)

Type of DOACs	Thrombosis		p-value*
	Yes	No	
Rivaroxaban	8 (17.4%)	38 (82.6%)	0.036
Apixaban	11 (26.8%)	30 (73.2%)	
Edoxaban	11 (45.8%)	13 (54.2%)	
Dabigatran	5 (50.0%)	5 (50.0%)	

*Chi-square test

Table IV: Effect of age, gender, area of residence, obesity, diabetes mellitus and hypertension on frequency of Hemorrhage in COVID-19 patients on DOACs (N=121)

Factors		Hemorrhage		p-value*
		Yes	No	
Age Groups	Up to 60 years	27 (46.6)	31 (53.4)	0.095
	> 60-years	20 (31.7)	43 (68.3)	
Gender	Male	24 (36.9)	41 (63.1)	0.641
	Female	23 (41.1)	33 (58.9)	
Obesity	Yes	18 (47.4)	20 (52.6)	0.193
	No	29 (34.9)	54 (65.1)	
Area of Residence	Rural	21 (36.2)	37 (63.6)	0.568
	Urban	26 (41.3)	37 (58.7)	
Diabetes Mellitus	Yes	24 (35.8)	43 (64.2)	0.447
	No	23 (42.6)	31 (57.4)	
Hypertension	Yes	27 (33.3)	54 (66.7)	0.077
	No	20 (50)	20 (50)	

*Chi-square test

DISCUSSION

The study was conducted among COVID-19 patients

with cardiometabolic diseases who were treated with direct-acting oral anticoagulants (DOACs). Thrombosis is one of the most common and well-known complications of COVID-19^{3,4}. The use of DOACs may offer more convenient and safer antithrombotic therapy with higher patient compliance than vitamin K antagonists⁸. Therefore, in this study, the frequency of thrombosis with DOACs in COVID-19 patients with cardiometabolic diseases was studied, and three factor Xa inhibitors (Rivaroxaban, Apixaban, and edoxaban) and a newly developed direct thrombin inhibitor (Dabigatran) were used to determine their effectiveness against thrombosis.

Previous studies reported that cardiometabolic multimorbidity is highly prevalent among COVID-19 patients and is independently associated with an increased risk of hospitalization and poorer clinical outcomes¹²⁻¹³ which is consistent with our findings, as 121 COVID-19 patients in our study were diagnosed with cardiometabolic diseases.

In our study, the mean age of COVID-19 patients with cardiometabolic diseases was 60 years, which is somewhat consistent with Pirae E 2023¹⁴, who found a mean age of 60 years in COVID-19 patients with cardiovascular diseases. Chen Q et al.¹⁵ reported a median age of 56 years in COVID-19 patients with cardiometabolic diseases. These studies show that the age of COVID-19 patients with cardiometabolic diseases is approximately 55 to 60 years.

Cohen et al. found that the COVID-19 death rate for men was 29.9% greater than for women¹⁶, which is consistent with our study, whereas the frequency of COVID-19 patients was significantly higher in males compared to females. Previous studies similarly show a higher prevalence of COVID-19 among males than among females^{14,15}.

The results of the study found that COVID-19 patients with cardiometabolic diseases were more common in non-obese (68.6%) compared to obese (31%) patients. At the same time, Hendren NS et al.¹⁷ reported that body mass index (BMI) affects morbidity and mortality in patients with COVID-19 and found obese patients face higher hospitalization rates and risks of death or ventilation from COVID-19, which is consistent with our study, which may be due to the small sample size of our study. The sample size was initially based on an anticipated 8.5% thrombotic event frequency; the observed rate was substantially higher. This discrepancy likely reflects the elevated risk profile and high burden of cardiometabolic multimorbidity in our cohort. While this higher event rate increases the study's statistical power to detect treatment effects, it also highlights a previously underestimated prothrombotic intensity in this population compared to earlier estimates. Further, our investigations found that hypertension and diabetes mellitus were most common among COVID-19 patients with cardiometabolic diseases, consistent with previous studies showing a high prevalence of hypertension and diabetes mellitus in COVID-19

patients with cardiometabolic diseases^{15,18}. However, age, diabetes mellitus and hypertension with DOACs did not significantly affect the occurrence of thrombosis and hemorrhage in our study. Cohen KR 2022¹⁶ reported a 35.8% higher rate of thrombotic diagnosis in men than in women, consistent with our study. In contrast, we found a higher rate of thrombosis in males than in females. Wilcox et al. also found that 34% of hospitalizations resulted in mortality or thrombosis, and that men were more likely to have these events (36% vs 29% in women, $p < 0.001$)¹⁹. Sattar N 2020²⁰ reported that obesity has negative impacts on lung function, reducing forced expiratory volume and forced vital capacity, in addition to cardiometabolic and thrombotic implications. Sattar N 2020²⁰ reported that higher relative fat mass is associated with adverse health effects and COVID-19 critical illness, especially in Asians, who may have lower fitness and more fat at lower BMI. Wang et al. reported that individuals with class I and III obesity had significantly increased risk-adjusted probabilities of venous thromboembolism (VTE) compared to patients without obesity²¹. Still, our study shows that thrombosis was not common in obese patients compared to non-obese patients, which may be because our patients were treated with DOACs. Magro C et al.²² reported that widespread cytokine activation in COVID-19 may trigger thrombosis by activating platelets and the complement system. COVID-19 is known to increase the risk of arterial and venous thrombosis, leading to a focus on thrombo-inflammation and antithrombotic therapy, especially anticoagulation²³. Rivera-Caravaca JM et al.²⁴ reported that patients receiving vitamin K antagonists before the diagnosis of COVID-19 demonstrated a 43% greater risk of thrombotic events and ischemic stroke within 30 days than those on DOACs, with comorbidities being taken into account using propensity score matching. Rivaroxaban was found to be more effective at preventing thromboembolism in a Brazilian study²⁵, consistent with our findings. The results of our study found that the frequency of thrombosis differed significantly among different DOACs, being highest in Dabigatran (50%), followed by edoxaban (45.8%). It was lowest for Rivaroxaban (17.4%), suggesting its effectiveness, but the sample size of Dabigatran was very small, which may affect the generalizability of these findings. Previous studies also show the effectiveness of Rivaroxaban. Ramacciotti et al. found that high-risk patients hospitalized with COVID-19 who received rivaroxaban 10 mg daily for 35 days post-discharge had a significantly lower rate of venous thromboembolism (VTE) and related mortality (3% vs 9%; $p = .0293$)²⁵. This suggests the prothrombotic state of COVID-19, supporting post-discharge anticoagulation in certain high-risk patients. Similarly, Weitz JI et al.²⁶ found that rivaroxaban effectively treats thromboembolism. They compared the effectiveness of Rivaroxaban and aspirin and found

that Rivaroxaban was more effective but associated with increased bleeding.

However, published data on DOACs in COVID-19 are inconsistent. Many COVID-19 patients who had been receiving DOAC therapy were shifted to heparins during hospitalization because it is anticipated that they will take drugs that interfere with DOACs or because they have coagulation system and homeostasis issues²⁷. The discrepancies in published data may have been the result of several factors, such as study populations, study designs, and the timing of the studies during the evolving pandemic. In addition to these, many antiviral and immunosuppressant medications used to treat COVID-19 have significant interactions with DOACs, making their dosing (drug-drug interactions) and effects unpredictable.

To summarize, the frequency of thrombosis in COVID-19 patients and the superior efficacy of Rivaroxaban compared to other DOACs in this patient population were examined. These findings are significant, particularly given existing discrepancies in the literature, and suggest that specific patient characteristics or underlying conditions may influence individual DOAC performance, which may help guide future management of COVID patients and the viral pandemic.

Limitation: A primary limitation of this study is that physicians selected DOACs based on preference rather than randomization, introducing uncontrolled confounding by indication that may have influenced the observed clinical outcomes. Additionally, the limited sample size and observational study design may limit the generalizability of these findings to broader, more diverse patient populations.

CONCLUSION

This study concludes that over a period of 30-day follow-up, COVID-19 patients with cardiometabolic diseases on DOACs developed 38.9% hemorrhage and 28.9% thrombosis. Male patients were at a higher risk of developing thrombosis. The frequency of thrombosis was lowest (17.4%) in patients on Rivaroxaban. Thus, rivaroxaban was relatively more effective than other DOACs such as Apixaban, Edoxaban, and Dabigatran.

Ethical permission: Nishtar Medical University, Multan, Pakistan, ERC approval letter No. 4120.

Conflict of interest: There is no conflict of interest between the authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Fatima S: Conception and design of the study, data collection and interpretation, writing – original draft

and finalized the manuscript.

Kaleemi S: Coordinated laboratory testing, contributed to the literature review and methodology section.

Huda NU: Performed formal analysis and drafted the results section of the manuscript.

Hafeez F: Assisted in patient recruitment, data entry, and reviewed the manuscript for accuracy.

Akhtar A: Helped in conducting the experiment and manuscript writing – review & editing.

Khan S: Critical review of the manuscript and help in reference correction.

REFERENCES

1. Lone SA, Ahmad A. COVID-19 pandemic—an African perspective. *Emerg Microbes Infect.* 2020; 9(1): 1300-1308.
2. Kim CW, Aronow WS, Frishman WH. Coronavirus disease 2019 and cardiometabolic disease. *Cardiol Rev.* 2022; 30(3): 123-128.
3. Nappi F, Nappi P, Gambardella I, Avtaar Singh SS. Thromboembolic disease and cardiac thrombotic complication in COVID-19: a systematic review. *Metabolites.* 2022; 12(10): 889.
4. Shah A, Donovan K, McHugh A, Pandey M, Aaron L, Bradbury CA et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. *Crit Care.* 2020; 24(1): 561.
5. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. *Am J Hematol.* 2020; 95(12): 1578-1589.
6. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. *Thromb Haemost.* 2020; 120(6): 949–56.
7. Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-Day results from the INSPIRATION randomized trial. *Thromb Haemost.* 2021; 325(16): 1620-30.
8. Lip GY, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. *Stroke.* 2018; 49(12): 2933-2944.
9. Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. *Res Pract in Thromb Haemost.* 2019; 3(4): 668-673.
10. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM et al. Apixaban for the treatment of venous thromboembolism associated with cancer. *N Eng J Med.* 2020; 382(17): 1599-1607.
11. Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. *Am J Med.* 2019; 132(5): 596–604.
12. Svensson P, Hofmann R, Häbel H, Jernberg T, Nordberg P. Association between cardiometabolic disease and severe COVID-19: a nationwide case-control study of patients requiring invasive mechanical ventilation. *BMJ Open.* 2021; 11(2): e044486.
13. Harrison SL, Buckley BJR, Rivera-Caravaca JM, Zhang J, Lip GYH. Cardiovascular risk factors, cardiovascular disease and COVID-19: An umbrella review of systematic reviews. *Eur Heart J Qual Care Clin Outcomes.* 2021; 7(4): 330–9.
14. Pirae E, Azarbaksh H, Moftakhar L, Valipour A. Epidemiological Features and Outcomes of COVID-19 in Patients With and Without Cardiovascular Disease. *Arch Iran Med.* 2023; 26(6): 316.
15. Chen Q, Wang L, Li C, Hu W, Fan Y, Chen Z et al. Chronic Cardio-Metabolic Disease Increases the Risk of Worse Outcomes Among Hospitalized Patients With COVID-19: A Multicenter, Retrospective, and Real-World Study. *J Am Heart Assoc.* 2021; 10(12): e018451.
16. Cohen KR, Anderson D, Ren S, Cook DJ. Contribution of the elevated thrombosis risk of males to the excess male mortality observed in COVID-19: an observational study. *BMJ Open.* 2022; 12(2): e051624.
17. Hendren NS, De Lemos JA, Ayers C, Das SR, Rao A, Carter S et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. *Circulation.* 2021; 143(2): 135-144.
18. Ciarambino T, Ciaburri F, Paoli VD, Caruso G, Giordano M, D'Avino M. Arterial hypertension and diabetes mellitus in COVID-19 patients: What is known by gender differences? *J Clin Med.* 2021; 10(16): 3740.
19. Wilcox T, Smilowitz NR, Seda B, Xia Y, Hochman J, Berger JS. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19. *Am J Cardiol.* 2022; 170: 112-7.
20. Sattar N, McInnes IB, McMurray JJ. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. *Circulation.* 2020; 142(1): 4-6.
21. Wang SY, Singh A, Eder MD, Vadlamani L, Lee AI, Chun HJ. Association of obesity with venous thromboembolism and myocardial injury in COVID-19. *Obes Res Clin Pract.* 2021; 15(5): 512-4.
22. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J et al. Complement associated

- microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res.* 2020; 220: 1-3.
23. Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. *Thromb Haemost.* 2021; 121(1): 76–85.
 24. Rivera-Caravaca JM, Harrison SL, Buckley BJR, Fazio-Eynullayeva E, Underhill P, Marín F et al. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. *Cardiovasc Diabetol.* 2021; 20(1): 176.
 25. Ramacciotti E, Barile Agati L, Calderaro D. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalization for COVID-19 (MICHELLE): an open-label, multicenter, randomized, controlled trial. *Lancet.* 2022; 399(10319): 50-59.
 26. Weitz JI, Lensing AW, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. *N Engl J Med.* 2017; 376(13): 1211-1222.
 27. Aly R, Gupta S, Singh B, Kaur P, Kim K, Gupta S. The use of direct acting oral anticoagulants in patients with COVID-19 infection. *J Commun Hosp Intern Med Perspect.* 2021; 11(2): 184–186.

